The Impact of Tranexamic Acid Administration in Reduction Mammaplasty: A Systematic Review

Previous studies demonstrated the effectiveness and safety of tranexamic acid (TXA) in several surgical specialties. Recent publications suggested that TXA may also be beneficial in plastic surgery, including breast procedures.

The aim of this study is to evaluate the impact of TXA in reduction mammaplasty by assessing several intraoperative and postoperative outcomes and the safety of its administration.

A systematic search was conducted according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analysis) guidelines on several online databases. Studies evaluating the outcomes of TXA administration in patients undergoing reduction mammaplasty, regardless of TXA dose and administration route were eligible for inclusion. Only studies with a control group were included. Risk-of-bias assessment was conducted using Cochrane and MINORS (Methodological Index for Non-Randomized Studies) tools.

Our systematic review included 7 studies: 3 randomized controlled trials and 4 retrospective cohorts involving 1234 female patients (2232 breasts), 741 of whom received TXA (60%). Four studies used topical TXA, 2 used intravenous (IV) TXA, one used locally infiltrated TXA, and another combined locally infiltrated TXA with IV TXA. Four studies demonstrated benefits from TXA administration, whereas 3 studies did not. Topical TXA used just before wound closure resulted in a 42% reduction in drain fluid output and a 10-times reduction in major hematoma. The administration of IV TXA during induction resulted in a 12-times reduction in major and minor hematoma. The combined use of IV and locally infiltrated TXA reduced intraoperative blood loss. No adverse effects were reported.

There is scientific evidence suggesting TXA may be effective and safe in reduction mammaplasty.